Pharma & Biotech - Page 12

Baxter International Inc. (NYSE: BAX) has initiated voluntary recalls of two injectable products after particulate matter contamination was identified in both solutions. The first recall involves two lots of 0.9% Sodium Chloride

Six months after its February 2026 launch, the White House’s TrumpRx platform has grown rapidly but continues to face scepticism from managed care professionals over genuine savings. The initiative launched with approximately

Akeso has announced a major clinical breakthrough, with its cancer drug ivonescimab meeting the primary endpoint of overall survival in a late-stage biliary tract cancer trial. The positive result comes from a

Pharmacists across the healthcare sector are increasingly calling for formal representation in policy discussions that directly shape the future of pharmaceutical care and patient outcomes. As one of the most accessible healthcare

Revolution Medicines has secured FDA approval for Rasonque, a once-daily tablet targeting RAS, a key protein driving tumour growth in most pancreatic cancer patients. The drug, known generically as daraxonrasib, is approved

Clinical digital out-of-home displays installed in medical waiting rooms are gaining recognition as a powerful and largely untapped channel for healthcare advertising. Patients sitting in waiting rooms represent a highly captive audience,

Lundbeck has signed an expanded agreement with Eversana to deploy the company’s AI commercialisation platform more broadly across its entire US commercial organisation. The brain disease specialist initially used Eversana’s AI-driven workflows

Rep. Nathaniel Moran of Texas says America’s political debate around China’s biotech industry is fundamentally missing the point on where the real threat lies. Moran, a Republican member of the House Select

Bausch + Lomb has developed a first-in-class combination eye drop targeting two of the primary underlying causes of dry eye disease simultaneously. The novel treatment combines 5% lifitegrast, the active ingredient in

Vikram Anand, president of compliance services at EVERSANA, has set out a vision for where pharmacovigilance infrastructure is headed next. Anand’s remarks close out a series of conversations with Pharmaceutical Commerce focused